Inpatient utilization of immune checkpoint inhibitors and clinical outcomes.
Jonathan WangChung-Shien LeeShirin AttarianNina KohnCraig DevoePublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
A majority of patients who received an immune checkpoint inhibitor while hospitalized were either discharged to hospice or expired by 90 days. An increased rate of death or discharge to hospice was observed for patients who were immune checkpoint inhibitor-naive prior to their admission.